Globus Medical, Inc. (GMED) Stock Price & Analysis
Globus Medical, Inc. (GMED) closed at USD 81.66 on Thursday, October 22, 2026, up 3.79% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 81.66; the Oct 22, 2026 session ranged USD 78.46–81.83 on volume of 1,293,937 shares. Market capitalization is —, with a 52-week range of USD 59.51–101.4 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GMED.md
Key facts (GMED)
- Last four reported quarters (through Jun 30, 2026): revenue $3.14B, net income $535M (17.0% margin), free cash flow $756M (SEC filings).
- Valuation: P/E 20.5x (avg 60.9x at the last 3 fiscal year-ends).
- 1 of 80 tracked superinvestors hold GMED (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.07 on a 1–5 scale) (14 analysts), mean target USD 100.92 (range 84–125).
- Total return with dividends: 1Y +30.0% vs S&P 500 +14.9%; 5Y +2.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.2, revenue estimate $792M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GMED)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $958M | $1.02B | $1.57B | $2.52B | $2.94B | $3.14B |
| Gross profit | $719M | $759M | $1.02B | $1.48B | $1.98B | — |
| Operating income | $172M | $228M | $133M | $166M | $480M | $640M |
| Net income | $149M | $190M | $123M | $103M | $538M | $535M |
| EPS (diluted) | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 | — |
| Free cash flow | $219M | $104M | $165M | $405M | $589M | $756M |
| Gross margin | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% | — |
| Operating margin | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% | 20.3% |
| Net margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% | 17.0% |
| Revenue growth | +21.4% | +6.8% | +53.3% | +60.6% | +16.7% | — |
| Cash + short-term investments | $443M | $446M | $518M | $890M | $557M | — |
| Total debt | — | — | $417M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GMED)
P/E 20.5x · P/S 3.5x · P/FCF 14.5x · P/B 2.3x · FCF yield 6.89% · Earnings yield 4.88% · Buyback yield (TTM) 2.02%
P/E at fiscal year-ends: Dec 2025 22.2x, Dec 2024 110.7x, Dec 2023 49.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (GMED)
1 of 80 tracked investors hold GMED. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Ruane Cunniff | Ruane Cunniff LP | 0.01% | $475K | Unchanged |
Analysts (GMED)
Consensus Buy (mean 2.07 on a 1–5 scale), 14 analysts; mean target USD 100.92 (low 84, high 125).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | RBC Capital | Target lowered | Outperform | $115 → $85 |
| 2026-08-07 | Wells Fargo | Target lowered | Overweight | $103 → $99 |
| 2026-07-28 | UBS | Initiated | Neutral | $82 |
| 2026-07-16 | Truist Securities | Target lowered | Buy | $115 → $100 |
| 2026-07-13 | RBC Capital | Target lowered | Outperform | $120 → $115 |
| 2026-07-09 | BMO Capital | Initiated | Outperform | $94 |
| 2026-07-08 | Stifel | Target lowered | Hold | $95 → $80 |
Total return (dividends reinvested) (GMED)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +30.0% | +2.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +30.1% | +0.4% |
| Volatility (annualized) | 45.2% | 38.7% |
| Max drawdown | -24.3% (Apr 2026→Oct 2026) | -44.7% (Oct 2021→Nov 2023) |
GMED analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.20 | $1.17 | +2.3% | $792.5M | 13 |
| Next quarter (ends Dec 2026) | $1.34 | $1.35 | -1.2% | $857.7M | 13 |
| Current fiscal year (ends Dec 2026) | $5.00 | $4.74 | +5.4% | $3.20B | 14 |
| Next fiscal year (ends Dec 2027) | $5.39 | $5.15 | +4.7% | $3.39B | 13 |
Key Statistics (as of October 23, 2026 at 09:28 UTC)
| Price | USD 81.66 |
|---|---|
| Change | ▲ 3.79% (up) |
| Previous Close | USD 81.66 |
| Open | USD 81.66 |
| Day Range | USD 78.46 – 81.83 |
| 52-Week Range | USD 59.51 – 101.4 |
| Volume | 1,293,937 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (GMED)
Nexqual's technical model rates GMED "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.47 (neutral) |
| vs SMA50 | Above (USD 78.24) |
| MACD | 0.6 (positive) |
Analyst Ratings (GMED)
Wall Street analysts rate GMED "Buy" based on 14 analysts, with a mean price target of USD 100.92 (range USD 84–125), per Nexqual as of October 23, 2026 at 09:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 100.92 |
| High Target | USD 125 |
| Low Target | USD 84 |
| Buy / Hold / Sell | 10 / 4 / 0 |
Earnings (GMED)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.2 |
| Revenue Estimate | $792.46M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.34 vs est 1.1 ▲ beat |
| 2026-03-31 | USD 1.12 vs est 0.92 ▲ beat |
| 2025-12-31 | USD 1.28 vs est 1.15 ▲ beat |
| 2025-09-30 | USD 1.18 vs est 0.78 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financials & Fundamentals (GMED)
| Total Revenue | $3.14B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.90% |
| Gross Margin | +68.97% |
| Operating Margin | +24.75% |
| Profit Margin | +17.03% |
| ROE | +11.81% |
| Debt / Equity | 0.02 |
| Current Ratio | 4.62 |
| Total Cash | $595.14M |
| Total Debt | $111.91M |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Ownership (GMED)
| Insider Ownership | +0.61% |
|---|---|
| Institutional Ownership | +92.29% |
| Shares Outstanding | 111.83M |
| Float | 110.92M |
| Short % of Float | +7.60% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GKOS | Glaukos Corporation | USD 176.69 | ▼ 0.09% |
| PODD | Insulet Corporation | USD 148.12 | ▲ 4.38% |
| BIO | Bio-Rad Laboratories, Inc. | USD 363.5 | ▲ 0.83% |
| PEN | Penumbra, Inc. | USD 324.96 | ▲ 0.43% |
| SNN | Smith & Nephew SNATS, Inc. | USD 30.88 | ▲ 5.64% |
| TXG | 10x Genomics, Inc. | USD 69.75 | ▼ 7.73% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt